Research Study Background
On 7th July 2017 Emmaus Medical Inc. got the US FDA positive nod for Endari (L-glutamine) a drug for Sickle cell Disease (SCD) for adults and children 5 and older. US FDA approved Endari as an Orphan drug, which will reduce the complications associated with blood disorder such as extreme side effects in the lungs and major pain.
Emmaus Medical Inc. have planned to launch its Orphan drug called Endari in an affordable price below $20K per year, so that patients can relieve their suffering.
Sentiment Analysis on Endari Drug Approval
Positive: Endari approval was quoted as an Impressive breakthrough - “Wow. ODAC votes 10-3 in favor of approving $EMMA's sickle cell treatment L-glutamine.”-Journalist (MCIPRIANO93)
Neutral: Majority of individual were either neutral or positive about the approval, and found sharing the information on social media platform- “The FDA approved Endari, the first new drug in nearly 20 years to treat sickle cell anemia complications.”- Unidentified Individual (SHTONTWEEDLTD)
Negative: Few people are seems to be sharing their concern around social media channel on Endari cost- “press release to sell expensive brand name l-glutamine powder. this is what fake news looks like smh”- Other Individual (MAUIMESCUDI)